Picture of Hansa Biopharma AB logo

HNSA — Hansa Biopharma AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-11.67%
3m-7.95%
6m-28.88%
1yr-61.89%
Volume Change (%)
10d/3m-1.63%
Price vs... (%)
52w High-67.24%
50d MA-8.9%
200d MA-34.86%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-78.5%
Return on Equity-65.27%
Operating Margin-1048.43%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for HNSA

After a strong run, what's next for investors in Hansa Biopharma Ab? background image

After a strong run, what's next for investors in Hansa Biopharma Ab?

If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone...  Since the dawn of the stock market, speculators have been captured by the tendency of prices to 'trend'.  When...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Hansa Biopharma AB EPS forecast chart

Profile Summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
July 10th, 2007
Public Since
October 17th, 2007
No. of Shareholders
18,000
No. of Employees
141
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
44,473,452

HNSA Share Price Performance

Upcoming Events for HNSA

Hansa Biopharma AB Annual Shareholders Meeting

Hansa Biopharma AB at William Blair Biotech Focus Conference

Q2 2022 Hansa Biopharma AB Earnings Release

Q3 2022 Hansa Biopharma AB Earnings Release

Similar to HNSA

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

FAQ

Or unlock with your email

Or unlock with your email